Pergolizzi Joseph V, Taylor Robert, LeQuang Jo Ann, Raffa Robert B, Bisney John
NEMA Research, Inc., Naples, FL, USA.
University of Arizona College of Pharmacy, Tucson, AZ, USA.
Pain Ther. 2018 Jun;7(1):37-57. doi: 10.1007/s40122-018-0095-8. Epub 2018 Apr 5.
Tapentadol is a novel pain reliever with apparently synergistic dual mechanisms of action, capable of addressing both nociceptive and neuropathic components of chronic pain. As an effective analgesic with good tolerability, tapentadol may be appropriate for patients suffering from severe chronic pain associated with low back pain (LBP) or osteoarthritis (OA). Efficacy studies of tapentadol in populations of patients with severe chronic LBP or OA pain suggest that tapentadol is non-inferior to oxycodone. Its tolerability, especially with respect to gastrointestinal (GI) side effects, may be better than that of other strong opioids in clinical trials and analyses of multiple trials. Patient satisfaction with tapentadol extended release for chronic noncancer pain syndromes is good. Although tapentadol has an opioid component with abuse liability, it appears to be a difficult opioid for tampering with less appeal to abusers than other opioids. For patients with severe LBP and OA pain, tapentadol appears to hold promise as a safe, effective therapeutic option.
曲马多是一种新型镇痛药,具有明显的协同双重作用机制,能够解决慢性疼痛的伤害性和神经性成分。作为一种耐受性良好的有效镇痛药,曲马多可能适用于患有与腰痛(LBP)或骨关节炎(OA)相关的严重慢性疼痛的患者。曲马多在重度慢性LBP或OA疼痛患者群体中的疗效研究表明,曲马多不劣于羟考酮。在临床试验和多项试验分析中,其耐受性,尤其是在胃肠道(GI)副作用方面,可能优于其他强效阿片类药物。患者对曲马多缓释剂治疗慢性非癌性疼痛综合征的满意度良好。虽然曲马多含有具有滥用倾向的阿片类成分,但它似乎是一种难以篡改的阿片类药物,对滥用者的吸引力低于其他阿片类药物。对于患有重度LBP和OA疼痛的患者,曲马多似乎有望成为一种安全、有效的治疗选择。